Vanguard Group Inc. raised its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 31.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,621,420 shares of the company’s stock after purchasing an additional 384,658 shares during the period. Vanguard Group Inc. owned about 3.44% of Karyopharm Therapeutics worth $14,675,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. American International Group Inc. raised its position in Karyopharm Therapeutics by 20.9% during the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after purchasing an additional 2,836 shares in the last quarter. Trexquant Investment LP bought a new stake in Karyopharm Therapeutics during the 2nd quarter valued at $202,000. State of Wisconsin Investment Board bought a new stake in Karyopharm Therapeutics during the 2nd quarter valued at $235,000. ProShare Advisors LLC raised its position in Karyopharm Therapeutics by 8.0% during the 2nd quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after purchasing an additional 2,021 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its position in Karyopharm Therapeutics by 38.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 27,988 shares of the company’s stock valued at $359,000 after purchasing an additional 7,789 shares in the last quarter. 59.23% of the stock is owned by institutional investors and hedge funds.

KPTI has been the subject of a number of research analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $19.00 target price (up from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. BidaskClub upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 25th. initiated coverage on Karyopharm Therapeutics in a report on Wednesday. They issued a “buy” rating and a $23.00 price target on the stock. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $17.33.

Karyopharm Therapeutics Inc. (KPTI) opened at $11.47 on Friday. Karyopharm Therapeutics Inc. has a fifty-two week low of $7.48 and a fifty-two week high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. equities analysts forecast that Karyopharm Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

In related news, SVP Christopher Brett Primiano sold 4,958 shares of the business’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total transaction of $55,777.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the transaction, the director now owns 2,882 shares in the company, valued at $31,702. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,653 shares of company stock worth $174,728. 14.71% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2017/11/19/karyopharm-therapeutics-inc-kpti-shares-bought-by-vanguard-group-inc.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.